PUTRAJAYA (Nov 27): Health director-general Tan Sri Dr Noor Hisham Abdullah said Malaysia’s procurement and use of the Covid-19 vaccine will depend on five aspects.
He said they are safety registration, supply, distribution, monitoring of side effects and evaluation of the vaccine’s effectiveness.
Dr Noor Hisham said the registration of the Covid-19 vaccine was a key condition that must be met to ensure it was effective and safe.
The vaccine needs to be registered with the FDA (United States Food and Drug Administration) and the Health Ministry’s National Pharmaceutical Regulatory Agency (NPRA), he said.
“If, for example, the pharmaceutical company Pfizer fails to register with FDA, then the whole deal will fall apart,” Dr Noor Hisham said referring to the agreement reached with the Pfizer for the supply of the vaccine.
Dr Noor Hisham said this when responding to Prime Minister Tan Sri Muhyiddin Yassin's announcement of the Malaysian government’s agreement with Pfizer to obtain 12.8 million doses of Covid-19 vaccines to meet the immunisation needs of 20% or 6.4 million Malaysians.
On the 6.4 million Malaysians who will receive the vaccine, Dr Noor Hisham said the vaccine would be given to those aged 18 and above with priority for health workers, frontliners and high-risk groups such as the elderly and those with low immunity.
He said currently 12 vaccines have been tested at the third phase of clinical research but there was still no complete report on any one of them.
Dr Noor Hisham said the Health Ministry (MoH) for now only received reports from the media and social media on the effectiveness of the vaccines.
"When the MoH studies a report, we (MoH) will set up a committee to look into the effectiveness, side effects and so on.
"This is important before the vaccine can be registered. If the vaccine cannot be registered, there may be safety issues and so on, and we (MoH) will not use the vaccine,” he said.
_____________________________________________
It appears that China one is the most reliable and effective in terms of meeting the above requirements....
Pfizer not receive approval from FDA and NPRA yet, and even though they managed to get it, 50m doze by this year production, domestic demand also not enough, the 1st queue from UK and EU countries already purchased more than next year productions which is 1.3 billion. Our PM announcement is only 'going to sign booking'. But our DG said those effectiveness are all from the news.The purchase must base on the proven of safe to use, which is report comes 1st, follow by the FDA and NPRA....
High 5, no need think so negatively, now everyone are switching from glove counter to vaccines counter, that's why you can see the big wave of more than 200mil turnover per day. You scare but to those who are big player had earned a lots from glove counter seeing this as kacang... When TG at RM4.. they say expensive, RM8 very high, RM16 roof top.. Eventually reach over RM27... We don't expect this as TG, we can treat it as Supermax... Keep for a while, unless you have no enough money and playing contra... give it at least 2 weeks....for expert they look at the chart, actually the chart looking good with momentum... Actually the news from Muhiddin is positive to the market, some of them outside will move in to vaccine counter. Just only you have sit on 143th floor... me too.. Add more if you afford.
@Hamster, dont bother them. Group of crooks down there.
@High, Yes PP is fixed at 91 cents.( after 10% discount of the average price of 1.00 ) . so it can not be down by 1.00 . it must be up high in order to attract PP investors to buy at 0.91.
another piece of good news, Solu has just been approved as SHARIAH-COMPLIANT SECURITY. it will attract more shariah funds into the pool.
The theme is Vaccine on the table now with solid hope and optimism.
with the above, i just cant see how the shares could be depressed
imagine you are the pp investor and pay for RM 0.91 per share, what would be the expected return as required by you ? 50% or 100 % ? I leave it to you to decide.
With the current price of 1.27, the pp investor has the instant gain of 40 . do you think PP investor is satisfied with 40% ? Again, i leave to your wild imagination.
it doesnt matter if Pfizer has stolen the show of what, solu can still ride on it as a raider who can capitalize on the theme of vaccine...... no big deal... expected to limit up next week.......
Not everyone will get injected with whichever Covid vaccine, some don't want, the rest are babies, kid, sick people and old people. Malaysia have approximately 31 million people.
I am confident Solution have a verbal go ahead when the China minister was in Msia . That is why Solution is building a bottling plant in KL .
from google. Nonetheless, Solution Group believes it is now the frontrunner in the vaccine race.
“We are the closest to the commercialisation of vaccines than anyone else,” says Solution Group managing director Barry Lim in an interview with The Edge.
The company is finalising a collaborative agreement with China’s vaccine specialist CanSino Biologics. The parties signed a memorandum of understanding (MoU) on Aug 3.
Shariah-compliant funds are investment funds governed by the requirements of Shariah law and the principles of the Muslim religion. Shariah-compliant funds are considered to be a type of socially responsible investing.
If the stock is shariah compliant, then it can be invested by shariah compliant funds.hence ,the stock creates another source of funds and opens up to more investors clienteles or base.
In a nutshell,its good for the co which is shariah compliant...
Solution spend much money to ready a facility to bottle the vaccine . so I think they will supply be 1 of the suppliers . There are already about 6 vaccine all ready to use , pending approval. you think the GOV have not sign them up yet ? if GOV not yet sign you think we can get the supply . many countries all wait and some have gone ahead sign supply contracts. Think about this .
from Edge. KUALA LUMPUR (Sept 23): Solution Group Bhd's subsidiary Solution Biologics Sdn Bhd and China-based CanSino Biologics Inc today signed a registration, manufacturing and commercialisation agreement, which will enable Solution Biologics to market and distribute in Malaysia the novel coronavirus vaccine developed by CanSino.
In a statement to Bursa Malaysia today, Solution Group said Solution Biologics will register with Malaysia's National Pharmaceutical Regulatory Agency to apply for the market authorisation certificate.
Solution Group said Solution Biologics "will establish a state-of-the-art fill and finish facility" to host a technology transfer for the filling, finishing and final quality control of CanSino's recombinant novel coronavirus vaccine.
The facility will be established at Solution Biologics' current premises at PT13796, Jalan Tekno Usahawan 2, Technology Park Malaysia in Bukit Jalil here.
no one knows how far it can goes but personally, this is really overvalued. may be they will fry it up to 3.00 one day, or even higher than pharma. who knows.
FDA Approval is Required by Law Federal law requires all new prescription drugs in the U.S. be shown to be safe and effective for their intended use prior to marketing. However, some drugs are available in the U.S. even though they have never received the required FDA approval.
As long as the china vaccine is registered by the National Pharmaceutical Regulatory Division (NPRA) ,then it can be marketed and used jn malaysia .
NPRAis an agency under the Ministry of Health Malaysia responsible for registering pharmaceutical products, traditional health supplements and notification of cosmetic products that are marketed in Malaysia.
Any vaccine to be marketed and used in USA must be registered and approved by FDA in USA.since pifzer is manufactured from USA,it must be registered and approved by FDA there.
I have smell a rat that coming few days, there will be an announcement on 3 phase in results, maybe not in Malaysia, because China has collaborated with few countries not only in Malaysia, China will not keep quiet and letting US to keep signing contract with other countries.
Beijing-based Sinovac, which makes a COVID-19 vaccine from inactivated virus, has efficacy trials underway in Brazil, Turkey, and Indonesia—but not in China.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Victorino
628 posts
Posted by Victorino > 2020-11-28 06:06 | Report Abuse
https://www.klsescreener.com/v2/news/view/759485